

Joint Pain Injection Market Revenue to Cross USD 6,996.88 million by 2028

Corticosteroid Segment to Lead Joint Pain Injection Market During 2021–2028

NEW YORK, UNITED STATES, November 1, 2022 /EINPresswire.com/ -- According to The Insight Partners new research study on "[Joint Pain Injection Market](#) Forecast to 2027 – COVID-19 Impact and Global Analysis – by Drug, Joint Type, and Distribution Channel," the market is expected to reach US\$ 6,996.88 million by 2028 from US\$ 3,667.45 million in 2020; it is estimated to grow at a CAGR of 8.5% from 2021 to 2028.

The report highlights trends prevailing in the joint pain injection market and factors driving its growth. The growth of the joint pain injection market is mainly attributed to the factors such as the high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, the high costs of joint repair therapies hinder the market growth.

Get Sample PDF Copy of this Report:

<https://www.theinsightpartners.com/sample/TIPRE00003536/>

What are the driving factors for the joint pain injection market across the globe?

The global joint pain injection market growth is mainly attributed to factors such the high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, the high costs of joint repair therapies hinder the market growth.

Chugai Pharmaceutical Co., Ltd., Teva Pharmaceuticals, Bioventus Inc., Fidia Pharma USA Inc., Flexion Therapeutics, Inc., SEIKAGAKU CORPORATION, Ferring B.V., Sanofi, Anika Therapeutics, Inc., and OrthogenRx are among the leading companies operating in the joint pain injection market.

Based on drug, the joint pain injection market, by drug, is segmented into hyaluronic acid, corticosteroid, and others. The corticosteroid segment held the largest market share in 2020, and it is expected to register the highest CAGR during the forecast period. Corticosteroids offer quick pain relief and help treat inflammation, pain, swelling, and redness. Further, surge in number of product approvals and launches is a key factor contributing to the market growth of the corticosteroids segment. For instance, in 2017, FDA approved ZILRETTA, an extended-release corticosteroid for the treatment of osteoarthritis-related knee pain.

The report segments the joint pain injection market as follows:

By Drug

Hyaluronic Acid

Corticosteroid

Others

By Joint Type

Knee

Foot and Ankle

Shoulder and Elbow

Hip

Others

By Distribution Channel

Retail Pharmacies

Hospitals Pharmacies

Others

Purchase a Copy of this Reports: <https://www.theinsightpartners.com/buy/TIPRE00003536/>

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.

Contact Us:

Sameer Joshi

The Insight Partners

+91 96661 11581

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/598930419>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.